MedPath

Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)

Conditions
Coronavirus Disease 2019 (COVID19)
Registration Number
NCT04443712
Lead Sponsor
Samia Girgis
Brief Summary

The objective of this study is to screen the patients seeking hospitalization in Ain Shams university hospitals and identify a cost effective tool for continuing screening the patients all through the epidemic period

Detailed Description

Study setting: Ain-Shams University Hospitals. It is a campus including the following main hospitals: Gynecology and Obstetrics, Oncology, Pediatrics, Psychiatry, Internal Medicine, surgical, cardiothoracic and Geriatrics.

Study population: All patients needing admission in Ain-Shams University Hospitals are eligible for the study.

Sample size: There is no incidence data published till now. Only the confirmed detected cases have been reported. We assumed that the community cases are around 10 times that of detected cases.

it was estimated to be 1900 patients with 95% confidence level given the frequency of positive screening 0.05% with precision ± 0.1%. 10

The patients will be enrolled in the study using consecutive sample till the sample size is achieved.

Study methods:

Every enrolled patient will be subjected to:

1. An interview questionnaire including personal data ( age, gender, residence , contact details ) , epidemiological data (history of contact to a COVID-19 case, History of travel), clinical data history ( Fever, Cough, sore throat)

2. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

3. Antibody IgM-IgG test for SARS-CoV-2

Statistical analysis:

Data will be validated, cleaned and entered in spreadsheet. SPSS program will be used for analysis.

Qualitative data will be presented in frequency and related percentage. Quantitative data with normal distribution will be presented in mean and standard deviation or median and interquartile for non-normally distributed data.

Incidence of positive screening test among the total will be calculated with 95% confidence interval.

Comparison between groups will be done using relevant suitable parametric or non-parametric tests. A "P" value of 0.05 is decided to be the level of significance.

Risk ratios will be calculated for estimation of risk with 95% confidence interval.

Cost per one positive detected screening test will be calculated (Total cost / total positive cases). The direct and indirect costs will be calculated by the laboratory department.

Ethical considerations:

The protocol will be submitted for approval by the University Ethical Research Committee.

The objectives and methods of the research will be explained to the participants.

An informed consent will be obtained from subjects willing to participate in the research and the subjects are free to withdraw from research anytime.

Confidentiality of the data will be highly secured. Positive cases will be reported to the Ministry of Health and Population (MOHP). The guidelines of isolation and treatment protocol of MOHP will be followed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1900
Inclusion Criteria

Not provided

Exclusion Criteria
  • Those who refuse to participate in the trial

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of the new COVID19 among hospitalized patients12 months

To measure the incidence of the new SARS-COV-2 (COVID19) among patients seeking hospitalization to Ain-Shams University Hospitals

Secondary Outcome Measures
NameTimeMethod
Cost of screening hospitalized patients12 months

To determine the cost of screening hospitalized patients

Trial Locations

Locations (1)

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center

🇪🇬

Cairo, Non-US, Egypt

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
🇪🇬Cairo, Non-US, Egypt
Fatma Soliman E Ebeid
Contact
01095569596
dr.fatma_ebeid@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.